STAT+: Telework helps FDA compete for scientists. What if it’s no longer an option?
WASHINGTON — The Food and Drug Administration needs to hire scores of in-demand scientists, and…
Category: biotechnology
STAT+: Skin patch for toddlers with peanut allergy shows promising results in late-stage trial
Parents of kids who have peanut allergies have to practice constant vigilance, whether that means…
STAT+: FDA reviewers had string of concerns about Sarepta’s gene therapy for Duchenne, documents show
Reviewers at the Food and Drug Administration concluded that Sarepta Therapeutics did not show that…
STAT+: Brigham creates institute focused on immunology with record $100 million gift
Brigham and Women’s Hospital will launch a new institute focused on immunology and inflammation, thanks…
STAT+: In small study, weight loss drug boosts immune cells that help fight cancer
Drugs like Ozempic and Wegovy have become immensely popular for their ability to help people…
STAT+: Pharmalittle: Big pharma maps legal strategy against U.S. drug pricing reform; U.S. pharma layoffs continue to climb
Top of the morning to you, and a fine one it is. The sun is…
STAT+: What to know about a pivotal FDA hearing on Sarepta’s gene therapy for Duchenne
On Friday, a committee of advisers to the Food and Drug Administration will meet to…
.jpg)
STAT+: EQRX abandons business plan around drug pricing, cuts jobs and programs
EQRx, a company that aimed to lower drug prices by introducing inexpensive me-too medicines, said…
‘Robbing Peter to pay Paul’: Obesity experts debate risks of new weight loss drugs
Amid rising demand for drugs like Wegovy, Ozempic, and Mounjaro that can lead to significant…
STAT+: Doudna talks cost, access issues looming over first CRISPR therapy
Jennifer Doudna may be just months away from seeing the first CRISPR-based therapy gain approval,…
STAT+: NIH grant recipients often fail to disclose agency support in patent applications
The National Institutes of Health may be the largest public funder of biomedical research in…
STAT+: Gilead foresees more growth in its HIV drugs
Gilead Sciences is famous — or perhaps, notorious — for its cure for hepatitis C….
Listen: Lilly’s Alzheimer’s success, a milestone FDA approval, & Moderna’s shrinking business
What’s the future of Alzheimer’s disease treatment? How do you pivot from a pandemic? And…
‘Are we better off with the information?’: Experts spar over the benefits of liquid biopsy to catch cancer
New technologies are making it possible to detect cancer earlier than ever — but the…
STAT+: A new list ranks large pharmaceutical companies by research and development
If you want a large pharmaceutical company to invent a new drug, your best bet…
Amid booming demand, Novo to hold back some doses of obesity drug Wegovy for new U.S. patients
Novo Nordisk, the maker of the wildly popular obesity drug Wegovy, said Thursday it would…
STAT+: Gene therapy has helped boys like Conner walk. Scientists are trying to keep it that way
In the beginning, Conner Curran ran up the stairs. It was a miraculous moment for…
STAT+: New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced…
STAT+: CAR-T research is flourishing but is hampered by outdated precautions, experts say
Twenty years ago, CAR-T cell therapy was not quite “believed in,” said Michel Sadelain, director…
For Eli Lilly’s head scientist, Alzheimer’s results cap a 25-year scientific quest
If you flip to the 1,031st page of the May 1998 edition of the Journal…
Now 18, the first child to ever receive CAR-T cancer therapy is ready for a new identity
The Food and Drug Administration approves dozens of cancer drugs every year, but the vast…
FDA approves first RSV vaccine, a long-sought scientific achievement
The Food and Drug Administration on Wednesday licensed the first-ever vaccine for respiratory syncytial virus,…
STAT+: Immunogen ovarian cancer drug shown to extend patients’ lives
A drug approved in November as the first new treatment for advanced ovarian cancer in…
STAT+: Eli Lilly’s Alzheimer’s therapy slowed patients’ rate of cognitive decline, data show
A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive…
STAT+: What to know about the upcoming readout of Eli Lilly’s experimental Alzheimer’s therapy
Eli Lilly is nearing the readout from a pivotal study of its experimental treatment for…
STAT+: Most of Canada’s public research universities get bad grades for ensuring access to drugs they discover
Despite significant public funding, most of the 15 largest public research universities in Canada failed…
STAT+: Astellas acquires Iveric Bio for $5.9B, entering competition to treat common cause of vision loss
Japanese drugmaker Astellas said late Sunday it would acquire eye drug developer Iveric Bio for…
STAT+: Sam Waksal and Jeremy Levin plot ‘the turnaround story of the century’
Over glasses of Chablis at Fleming by Le Bilboquet in Manhattan, two longtime friends and…
STAT+: Beyond Wegovy and Ozempic: Biotechs vie for piece of red-hot weight loss market with novel strategies
This is part of a series about new obesity drugs that are transforming patients’ lives,…
STAT+: Covid-19 burnished pharma’s reputation among patient groups, but access to medicines is now an issue
In the wake of the Covid-19 pandemic, the pharmaceutical industry enjoyed something of an afterglow,…
To prevent preeclampsia, experts push for broader blood pressure testing at home
Eleni Tsigas likens her first experience with preeclampsia to a plane crash. She was in…
STAT+: FDA warns of security vulnerability in Illumina’s DNA sequencing machines
The Food and Drug Administration warned health care providers Thursday that a security vulnerability in…
Listen: Explaining the E.U.’s pharma overhaul, Lilly’s booming business, & a long-awaited drug approval
Is a specter haunting Europe? Will Eli Lilly usurp Johnson & Johnson? And what does…
STAT+: Eli Lilly’s Mounjaro succeeds in second weight-loss study, paving way for FDA review
The drug giant Eli Lilly said Thursday that its diabetes drug Mounjaro helped patients with…
STAT+: Six months after launch, Bert Vogelstein’s latest blood testing startup gets acquired for $450 million
Six months after launch, a startup founded by three leaders in the blood testing field…
STAT+: Pharma executives flood Bill Cassidy with campaign cash
WASHINGTON — Sen. Bill Cassidy’s new perch as the top Republican on the Senate health…
STAT+: FDA approves Seres microbiome drug, as field advances
The Food and Drug Administration on Wednesday approved a new drug from Seres Therapeutics that…
.jpg)
STAT+: Alnylam’s ‘upstream’ Alzheimer’s treatment shows early promise
An early-stage Alzheimer’s disease treatment from Alnylam Pharmaceuticals showed promising signs of benefit in a…
STAT+: Early findings in gene therapy death suggest CRISPR was not the cause
In February, four months after the first patient in a designer CRISPR therapy suddenly died,…
STAT+: EU releases proposed pharma overhaul, cutting period of market exclusivity
LONDON — The European Commission on Wednesday unveiled a long-awaited proposed update for how the…
STAT+: RNA startup Orbital cinches $270 million investment
A new biotech founded by veterans of Alnylam Pharmaceuticals, Beam Therapeutics, ARCH Venture Partners, and…
STAT+: FDA approves new treatment from Biogen for rare form of ALS
The Food and Drug Administration on Tuesday granted conditional approval to a new treatment for…
STAT+: Sens. Bernie Sanders, Bill Cassidy reach deal on PBM, generic reform
WASHINGTON — Senate health committee leaders Bernie Sanders and Bill Cassidy on Tuesday announced an agreement…
STAT+: Morphic study shows promise — and blockbuster potential — for a pill to treat ulcerative colitis
Morphic Therapeutic said Tuesday that an experimental oral medicine induced complete remissions in 26% of…
‘There’s a huge fatphobia problem in the eating disorder world’: Even in treatment, weight stigma fails patients
This is part of a series about new obesity drugs that are transforming patients’ lives,…
STAT+: Maryland pushes first-of-its-kind bill to promote alternatives to animals in biomedical research
Amid a push to use fewer animals in medical research, Maryland is on the verge…
STAT+: Bluebird submits sickle cell gene therapy to FDA for approval
Gene therapy developer Bluebio Bio said Monday that it has submitted a long-awaited application asking…
Listen: Sarepta’s pivotal moment, biotech’s big week, & the future of Covid boosters
How can you be sure a gene therapy is working? What does $11 billion get…
STAT+: Leaked study results show a CAR-T from J&J providing big benefit for patients with multiple myeloma
The CAR-T cancer therapy called Carvykti, made by Johnson & Johnson and Legend Biotech, reduced…
STAT+: Novel strategy of attacking sugars on cancer cells to free immune system shows promise in early tests
ORLANDO, Fla. — Many cancer cells shroud themselves in a thicket of complex sugars called…